Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple ALK fusions treated with tyrosine kinase inhibitors
نویسندگان
چکیده
Background: Patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) fusions may benefit from ALK-tyrosine inhibitors (ALK-TKIs). However, few studies have analyzed the clinical outcome in patients multiple ALK fusions, including double or triple fusions. Here, our study aimed to analyze impact of on efficacy receiving ALK-TKIs NSCLC patients.
منابع مشابه
Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
PURPOSE The aim of this study was to develop a pragmatic nomogram for prediction of progressionfree survival (PFS) for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in EGFR mutant non-small cell lung cancer (NSCLC). MATERIALS AND METHODS A total of 306 recurred or metastatic NSCLC patients with EGFR mutation, who received EGFR TKIs, were enrolled in this study. W...
متن کاملTyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK)
Lung cancer is a tumor pathology that includes a group of neoplasms with different biological characteristics, which determine the course of the disease and the potential treatment response depending on the subtype diagnosed. Non-small lung carcinoma corresponds to 85 % of all lung cancers. Adenocarcinoma is the most common histologic subtype of this group. In the United States approximately 13...
متن کاملDistinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders
INTRODUCTION Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC...
متن کاملMolecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
INTRODUCTION Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have become a treatment option in non-small-cell lung cancer (NSCLC) patients. However, despite their use in this disease, a significant number of patients will eventually develop resistance and relapse. In this study, we aimed to characterize several molecular events involved in potential resistance mechanis...
متن کاملRole of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
BACKGROUND Approximately 10% of unselected non-small-cell lung cancer (NSCLC) patients responded to the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, resistance mechanisms are not well understood. We evaluated several potential biological markers of intrinsic EGFR-TKIs-resistance in NSCLC. MATERIALS AND METHODS pAKT, pERK, cSRC, E-cadherin, cMET[p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational lung cancer research
سال: 2023
ISSN: ['2226-4477', '2218-6751']
DOI: https://doi.org/10.21037/tlcr-23-484